La Jolla, CANCT06711705Now EnrollingIRB Ready

Multiple Myeloma Clinical Trial in La Jolla, CA

Access cutting-edge multiple myeloma treatment through this phase 2 clinical trial at a research site in La Jolla. Study-provided care at no cost to qualified participants.

Sponsored by University of California, San Diego

Quick Self-Assessment

See if you qualify for this La Jolla location

Preparing your pre-screening questions…

Expert Care in La Jolla

Access multiple myeloma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related multiple myeloma treatment provided free

Apply for This La Jolla Location

Check if you qualify for this multiple myeloma clinical trial in La Jolla, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to La Jolla

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit La Jolla site if eligible
  4. 4Begin participation

About This Multiple Myeloma Study in La Jolla

This study evaluates the efficacy of elranatamab alone in patients with relapsed and/or refractory Multiple myeloma who has previously received 1 to 3 combinations of treatment.

Sponsor: University of California, San Diego

Who Can Participate

Inclusion Criteria

Provision of signed and dated informed consent form
Stated willingness to comply with all study procedures and availability for the duration of the study
Prior diagnosis of relapsed/refractory MM and have received 1 to 3 prior lines of therapy as defined by the IMWG criteria (Rajkumar et al., 2014) including anti-CD38 monoclonal antibody, proteosome inhibitor (PI), and immunomodulatory drug (IMiD), and BCMA-directed chimeric antigen receptor T-cell (CAR T-cell) therapy
Refractory is defined as having disease progression while on therapy or within 60 days of last dose in any line, regardless of response.
If participant has not received BCMA-directed CAR T-cell therapy, must be ineligible for CAR T-cell therapy or deferred such treatment by participant
Aged greater or equal to 18 years
Measurable disease as defined by any of the following:
Serum M-protein level ≥ 0.5 g/dL by serum protein electrophoresis (SPEP), or
Urine M-protein ≥ 200mg/24 hours by urine protein electrophoresis (UPEP), or
Involved serum free light chain ≥ 10 mg/dL (≥100mg/L) AND an abnormal serum free light chain ratio in patients without measurable disease in the serum or urine
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
Adequate hematological function defined as
Absolute neutrophil count (ANC) ≥1,000/mm3 (G-CSF not permitted for at least 1 week prior to the first dose of elranatamab)
Hemoglobin ≥8.0 g/dL (transfusion support is permitted if completed at least 1 week prior to planned start of dosing)
Platelet count ≥75,000/mm3 or ≥50,000/mm3 if \>50% involvement with plasma cells in the screening bone marrow (transfusion support is permitted if completed at least 1 week prior to planned start of dosing)
Adequate renal function with estimated creatinine clearance (CrCl) ≥30 mL/min as calculated using Cockcroft-Gault equation.
Adequate liver function defined as
Aspartate and alanine aminotransferase (AST and ALT) ≤2.5 x upper limit of normal (ULN); ≤5.0 x ULN if there is liver involvement by the tumor.
Alkaline phosphatase ≤2.5 x ULN (≤5 x ULN in case of bone metastasis).
Total bilirubin ≤2.0 mg/dL, except in patients with Gilbert Syndrome who must have a total bilirubin less than 3.0 mg/dL.
Able to receive outpatient treatment of elranatamab by meeting the following criteria:
Lives within 30minutes from the site of medication administration
Reliable caregiver present, who is able to watch participant continuously for at least until 48 hours after administration of first full treatment dose
No history of grade 3-4 CRS or grade 3-4 ICANS from other immune effector cell or bispecific antibody therapies
Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade ≤1
Serum pregnancy test (for females of childbearing potential) negative at screening. a. Female patients of non-childbearing potential must meet at least 1 of the following criteria: i. Achieved postmenopausal status, defined as follows: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; status may be confirmed with a serum follicle stimulating hormone (FSH) level confirming the postmenopausal state. ii. Have undergone a documented hysterectomy and/or bilateral oophorectomy. iii. Have medically confirmed ovarian failure. b. All other female patients (including female patients with tubal ligations) are considered to be of childbearing potential.
Agreement to adhere to Lifestyle Considerations (see section 5.3 and Appendix 2) throughout study duration

Exclusion Criteria

Subjects with smoldering multiple myeloma, IgM multiple myeloma, Waldenstrom's macroglobulinemia, amyloidosis, POEMS syndrome, and primary and secondary plasma cell leukemia, defined as circulating plasma cells ≥ 5%
Extramedullary relapse who does not meet criteria for measurable disease as above
Active malignancy other than Multiple Myeloma requiring treatment in the past 3 years, with the exception of successfully treated non-metastatic squamous or basal skin carcinoma
Known CNS involvement by multiple myeloma
Active, uncontrolled autoimmune disorders
Active uncontrolled infection. Active infections must be resolved and/or controlled at least 14 days prior to enrollment.
Radiation therapy within 2 weeks prior to study entry (bone lesions requiring radiation may be treated with limited \[ie, ≤25% of bone marrow in field\] radiation therapy during this period).
Last systemic treatment within 2 weeks or 5 half lives, whichever is shorter. Subjects can receive a maximum of 160mg of dexamethasone or equivalent during screening, but at least 7 days prior to start of therapy.
Last radiation treatment to multiple sites within 2 weeks and single site within 1 week
History of autologous stem cell transplant within 100 days prior to study enrollment.
History of allogeneic transplant within 1 year prior to study enrollment or active graft versus host disease.
On immunosuppressive therapy for concurrent comorbid conditions
Other major uncontrolled medical comorbidities that may put patients at risk of serious adverse event with treatment with study medication.
Clinically significant, uncontrolled cardiac disease
Grade ≥2 peripheral sensory or motor neuropathy
History of Guillan-Barre syndrome
Other surgical (including major surgery within 14 days prior to enrollment) or psychiatric conditions including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
Previous administration with an investigational drug within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer).
Pregnancy or lactation
Known or suspected hypersensitivity to the study intervention or any of its excipients.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in La Jolla?

Yes, this clinical trial (NCT06711705) has an active research site in La Jolla, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Multiple Myeloma Treatment Options in La Jolla, CA

If you're searching for multiple myeloma treatment options in La Jolla, CA, this clinical trial (NCT06711705) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our La Jolla research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced multiple myeloma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all multiple myeloma clinical trials near you to find additional studies recruiting in your area.

More Multiple Myeloma Trials in La Jolla, CA

See all multiple myeloma clinical trials recruiting in La Jolla — not just this study.

Browse Multiple Myeloma Trials in La Jolla →

Browse More Trials by Condition

Multiple Myeloma TrialsAll Conditions →

Ready to Join in La Jolla?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · La Jolla, CA